“…* P<0.05 vs. tumor size ≤3 cm of most benign and low-grade malignant tumors and their predilection for the young or middle-aged population (Valsangkar et al, 2012), patients could benefit more from parenchyma sparing and "no gastrointestinal tract disturbance" surgical procedures such as tumor EU. EU, first reported in 1898 by Ernesto Tricomi (Howard and Hess, 2002), has been widely accepted as an alternative procedure for benign and low-grade malignant pancreatic tumors including endocrine tumors (Ramage et al, 2005;Norton, 2006;Crippa et al, 2007;Falconi et al, 2010;Hackert et al, 2011;Zhang et al, 2013), SCAs, MCNs, SPTs, branch-duct IPMNs, pseudocysts, and so forth (Talamini et al, 1998;Kiely et al, 2003;Madan et al, 2004;Papavramidis and Papavramidis, 2005;Crippa et al, 2007;Ge et al, 2010;Hackert et al, 2011;Turrini et al, 2011;Zhang et al, 2013). EU has proved to be a procedure characterized by less operation time and blood loss, faster recovery, and preserving more of the pancreas parenchyma, compared with standard procedures (Casadei et al, 2010;Falconi et al, 2010;Hackert et al, 2011;Yan et al, 2015).…”